-
Eur Radiol: How to use the imaging group to predict the ineffective resection of intrahepatic cholangiocarcinoma?
Time of Update: 2021-03-19
Figure 1 Comparison of the ROC curve for predicting invalid resection in the clinical model, radioomics model, and combined model training (a) and validation (b) cohort.
-
Neuro Oncol: MEK-1/2 inhibitor selumetinib significantly improves the prognosis of recurrent/progressive low-grade glioma in children
Time of Update: 2021-03-19
Sumetinib is well tolerated in children with relapsed/progressive OPHGs, and it can also improve imaging remission, PFS and visual prognosis, and prolong the stable period of disease.
-
NICE: It is recommended to combine Kisqali (ribociclib) with Fulvestrant for the treatment of locally advanced or metastatic breast cancer
Time of Update: 2021-03-19
The fund NICE said in a statement that new evidence shows that fulvestrant combined with Kisqali treatment can significantly extend the life of breast cancer patients compared to fulvestrant alone.
-
JTO: Efficacy and safety of Rova-T combined with nivolumab or ipilimumab in the treatment of extensive-stage small cell lung cancer
Time of Update: 2021-03-19
This study is an open phase I/II study to evaluate the safety and effectiveness of Rova-T in combination with nivolumab or ipilimumab for the previously treated extensive-stage small cell lung cancer (ES SCLC) .
-
Eur Radiol: Whether it is radiomics or diagnostic evaluation, how can we better delineate high-grade gliomas on MRI images?
Time of Update: 2021-03-19
Recently, a study published in European Radiology explored the value of contrast enhancement (CE) turbo spin echo black blood (BB) sequence in the imaging diagnosis of untreated high-grade gliomas (HGGs) , and The comparison with the diagnostic performance of the CE TFE sequence shows that CE BB imaging has more advantages in delineating tumor boundaries, showing tumor invasion of adjacent brain tissues and displaying satellite lesions.
-
Eur Radiol: How to judge whether lung cancer has invaded the visceral pleura?
Time of Update: 2021-03-19
diagnosis Recently, a study published in the journal European Radiology developed and verified a preoperative CT-based deep learning model for predicting the VPI of early lung cancer.
Recently, a study published in the journal European Radiology developed and verified a preoperative CT-based deep learning model for predicting the VPI of early lung cancer.
-
Cancer: Cancer can significantly increase the cardiovascular mortality of patients with atrial fibrillation!
Time of Update: 2021-03-19
10) riskIn short, cancer increases the risk of all-cause mortality, hemorrhage and cerebral hemorrhage in patients with atrial fibrillation.
Cancer increases the risk of all-cause mortality, hemorrhage and cerebral hemorrhage in patients with atrial fibrillation.
-
Superior to crizotinib, FDA approved lauratinib as the first-line treatment for ALK-positive non-small cell lung cancer (NSCLC) patients
Time of Update: 2021-03-19
Recently, the FDA approved Pfizer's Lorbrena (lorlatinib) supplementary new drug application (sNDA) for expanded indications for the first-line treatment of patients with anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer ( NSCLC ).
For ALK-positive advanced non-small cell lung cancer patients, LORBRENA is a revolutionary drug.
-
BeiGene's PD-1 6th indication has been accepted for the treatment of non-small cell lung cancer
Time of Update: 2021-03-19
(Tilelizumab ) is a new indication for the treatment of second- or third-line locally advanced or metastatic non-small cell lung cancer ( NSCLC ) patients who have undergone disease progression after receiving platinum-based chemotherapy .
-
Commuting for more than 20 minutes, the risk of cancer is as high as 10%
Time of Update: 2021-03-19
"Researchers at the University of California, Riverside believe that the presence of benzene and formaldehyde in the air poses a higher threat to the health of office workers than the harmful substances detected in interior items .
-
CEBP: Stop drinking!
Time of Update: 2021-03-19
Recently, a study published in Cancer Epidemiology Biomarkers & Prevention showed that compared with never/rarely drinking SSB breast cancer patients, the all-cause mortality rate of drinking more than 5 times a week was 62% higher, and the breast cancer mortality rate 85% higher.
-
JTO: Three-region and two-region lymph node dissection for middle and lower esophageal cancer: long-term results of a randomized clinical trial.
Time of Update: 2021-03-19
In summary, for patients with middle and lower thoracic esophageal cancer, there is no improvement in OS or DFS after esophagectomy with three-regional lymph node dissection compared to the second with its lymph node dissection.
-
Eur Radiol: Prediction of MYCN expansion in neuroblastoma based on CT radiomics
Time of Update: 2021-03-19
Recently, a study published in the journal European Radiology constructed CT-based radioomics features and evaluated its diagnostic performance in predicting MYCN amplification (MNA) in children with neuroblastoma , establishing a non-invasive approach for the clinic Methods of detecting and evaluating MNA provide the possibility.
-
The global cancer drug giant ranks TOP10
Time of Update: 2021-03-19
S. dollars (approximately RMB 93 billion), contributing 33% of the total revenue and 91% of the oncology business.
The CD38 monoclonal antibody drug daratumomab and the BTK inhibitor ibrutinib are Johnson & Johnson's two major oncology products, which together contribute more than 8 billion U.
-
Daiichi Sankyo dismantles nearly 4.7 billion yen of mature drugs, accelerating the transformation into the field of oncology
Time of Update: 2021-03-19
Among them, 6 products will be transferred to Alfresa Pharmaceuticals in the form of a company split, which will take effect on December 1, 2021.
According to reports, even after the sale, Daiichi Sankyo will still be responsible for product manufacturing for the time being.
-
NEJM: BCMA targeted CAR-T cell therapy Idecabtagene Vicleucel (Ide-cel) achieved positive results
Time of Update: 2021-03-19
In all dose levels and multiple high-risk subgroups, including a large number of patients with high-risk cytogenetics, triple or five-fold refractory disease, high tumor burden at baseline, and extramedullary disease, clinically meaningful responses were reported.
In the KarMMa study, ide-cel is consistent with the known toxicity of CAR-T cell therapy, regardless of the dose level.
-
JNCC: National Cancer Center Hejie Academician Team Authoritatively Releases China's Latest Cancer Epidemic Data
Time of Update: 2021-03-19
cn/ipsen/sporty/show-details/3074/2">digestivetract tumors and cancer highUrban areas, lung cancer, breast cancer , colorectal colorectal cancer and other high; the rural areas of esophageal cancer,Stomach cancer , liver cancer and othermedsci.
cn/ipsen/sporty/show-details/3074/2">digestive tract cancer, cervical cancer mortalityUrban areas of colorectal cancer, breast cancer, prostate cancer and other high mortality rate; rural areas, lung cancer, medsci.
-
In less than half a year, the cancer has changed from "soya bean" to "fist"!
Time of Update: 2021-03-19
Chen Jiaxiang, the attending doctor and deputy chief physician of the Department of Neurosurgery of Guangzhou Red Cross Hospital, said that the old man is not only old, but also suffering from high blood pressure, diabetes, heart disease and other diseases.
-
New progress has been made in the treatment of advanced ovarian cancer, and GEN-1 has achieved gratifying results in Phase I/II clinical trials!
Time of Update: 2021-03-19
Ovarian cancerBiopharmaceutical company Celsion today announced the latest information on the I/II OVATION 2 study of GEN-1 for the treatment of advanced ovarian cancer.
immunityThe OVATION 2 study explored the effectiveness and safety of GEN-1 combined with standard new adjuvant chemotherapy (NACT) in the treatment of newly treated stage III/IV ovarian cancer.
-
Medical insurance prices for melanoma dual-target and dual-indication drugs will be officially implemented in 2020, helping more patients to reduce the burden
Time of Update: 2021-03-19
There are two indications for the drug combination to be included in the 2020 medical insurance catalogue: one is the advanced treatment of unresectable or metastatic melanoma with BRAF V600 mutation positive; the other is the treatment of patients with BRAF V600 mutation positive stage III melanoma after complete resection Adjuvant treatment.
